A Phase 3 interventional study of Brensocatib 10 mg and Brensocatib 25 mg in Non-Cystic Fibrosis Bronchiectasis, sponsored by Insmed Incorporated. Completed at 373 sites in 36 countries. Open to participants aged 12 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-12-16.
Sponsored by Insmed Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Bronchiectasis with a site in United States — 21 open to participants now, 23 under way, 2 of them phase 3. Bronchiectasis · United States.
Among the 65 studies in Bronchiectasis with a site in United States, this one has the largest enrollment of the 52 interventional ones that give a count, is one of 4 that started in 2020, is one of 14 in phase 3, and was the 35th registered.
404 studies on the registry are indexed under Bronchiectasis; 125 are open to participants now.
Browse Bronchiectasis studies →21 of the 65 studies in Bronchiectasis with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
UCB Biopharma SRL · Sites in United States
Ages 18–80
Indiana University · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 22 more countries
Ages 12+
GlaxoSmithKline · Sites in United States, Argentina, China and 9 more countries
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 93 Bronchiectasis studies recruiting now, 50 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 12 take children under 18; 26 take healthy volunteers.
This study: 12 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
First in 1988; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,767 is above the median of 60 across 263 interventional studies indexed under Bronchiectasis.
Median enrollment 78 across the 52 interventional studies, 100 across the 13 observational. Of the 39 that completed or were terminated, 20 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 65 have an industry lead sponsor. The 10 most frequent:
Insmed Incorporated is the lead sponsor of 50 studies on the registry; 8 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 8 (29%) have results posted.
Insmed Incorporated has 4 studies filed under Bronchiectasis — fewer than ten, so there is no comparison to draw.
8 of the studies in Bronchiectasis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06872892Phase 3Boehringer IngelheimThe AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis | 2027-06-15 |
| NCT05860803Mayo ClinicBreathing Training and Exercise Capacity in Non-CFB | 2026-12-01 |
| NCT07135284Synchrony-Medical, LtdReal Life Evaluation of the LibAirty Airway Clearance System in Adults With Bronchiectasis (RELACS) | 2027-02 |
| NCT05846230Boehringer IngelheimClairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine | 2027-03-31 |
| NCT03839992Gelb, Arthur F., M.D.Detection of Unsuspected Small Airways Obstruction in Cystic Fibrosis | 2027-04-25 |
Add all 8 to your calendar (.ics) → With an account.
Among the 65 studies in Bronchiectasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations (PEs) over the 52-week treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Provide their signed study to participate.
a. Adolescent participants must have signed study assent form to participate, and the adolescent's parent or legal guardian must have provided signed informed consent for the adolescent to participate.
At least 2 PEs defined by need for antibiotic prescription by a physician for the signs and symptoms of respiratory infections in the past 12 months before the Screening Visit.
a. Adolescent participants are required to have at least 1 pulmonary exacerbation in the prior 12 months.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive brensocatib 10 mg, tablets orally, once daily, for 52 weeks.
Drug: Brensocatib 10 mg
Participants will receive brensocatib 25 mg, tablets orally, once daily, for 52 weeks.
Drug: Brensocatib 25 mg
Participants will receive a brensocatib-matching placebo, tablets orally, once daily, for 52 weeks.
Drug: Placebo
Oral tablet.
Also known as: INS1007
Oral tablet.
Also known as: INS1007
Brensocatib-matching oral tablet.
Annualized Rate of Pulmonary Exacerbations (PEs)
PE was defined as having 3 or more of these symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics: 1. Increased cough 2. Increased sputum volume or change in sputum consistency 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis. A severe pulmonary exacerbation was that required intravenous (IV) antibacterial drug treatment and/or hospitalization. A minimum of 14 days must have occurred between one exacerbation onset and the next. Any exacerbation that occurred less than 14 days from the prior exacerbation was not considered a new exacerbation. Independent adjudication committee with pulmonary physicians adjudicated reported PE events to see if they fulfil the protocol definition. The rate of PE was analyzed using the negative binomial model.
Time frame: Up to Week 52
Time to First PE
PE was defined as having 3 or more of following symptoms for at least 48 hours resulting in physician's decision to prescribe antibiotics:1.Increased cough2.Increased sputum volume or change in sputum consistency3.Increased sputum purulence4.Increased breathlessness \&/or decreased exercise tolerance5.Fatigue \&/or malaise6.Hemoptysis.Severe PE were those requiring IV antibacterial drug treatment \&/or hospitalization. Minimum of 14 days must have occurred between one exacerbation onset and next. Any exacerbation that occurred within 14 days of prior exacerbation was not considered a new exacerbation. Time to first PE was calculated from randomization date to onset date of the first exacerbation. Participants who did not have exacerbation at end of 52-week treatment period were considered as censored at date of Week 52 in Cox proportional hazard model. Independent adjudication committee with pulmonary physicians adjudicated reported PE events to see if they fulfil protocol definition.
Time frame: Up to Week 52
Responder Status for Exacerbation-Free Over the 52-Week Treatment Period
Responder status was based on percentage of participants who were exacerbation free over 52-weeks of treatment period. Pulmonary exacerbation was defined as having 3 or more of the following symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics: 1. Increased cough 2. Increased sputum volume or change in sputum consistency 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis. A minimum of 14 days must have occurred between one exacerbation onset and the next. Any exacerbation that occurred less than 14 days from the prior exacerbation was not considered a new exacerbation. Independent adjudication committee of pulmonary physicians adjudicated reported PE events to see if they fulfill protocol definition. For discontinuation prior to Week 52 without having experienced a confirmed PE, responder status was imputed by multiple imputation.
Time frame: Up to Week 52
Change From Baseline at Week 52 in Postbronchodilator Forced Expiratory Volume in 1 Second (FEV1)
FEV1 was used to assess lung function and is the maximum amount of air that can be forced out in one second after first second after taking a forced expiration as measured by spirometer. Postbronchodilator FEV1 tests included spirometry tests performed referred to the spirometry performed within 30 minutes after administration of bronchodilator (4 puffs of salbutamol/albuterol, terbutaline or ipratropium). A positive change from baseline indicates an improvement in lung function. Baseline was the most recent non-missing assessment determined as best effort prior to the first dose of the investigational product.
Time frame: Baseline, Week 52
Annualized Rate of Severe PEs
Pulmonary exacerbation was defined as having 3 or more of the following symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics: 1. Increased cough 2. Increased sputum volume or change in sputum consistency 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis. A severe PE was defined as those requiring IV antibacterial drug treatment and/or hospitalization. A minimum of 14 days must have occurred between one exacerbation onset and the next. Any exacerbation that occurred less than 14 days from the prior exacerbation was not considered a new exacerbation. Independent adjudication committee with pulmonary physicians adjucated reported PE events to see if they fulfil the protocol definition. The rate of PE was analyzed using the negative binomial model.
Time frame: Up to Week 52
Change From Baseline at Week 52 in Quality of Life Questionnaire - Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score in Adult Participants
The QOL-B is a validated, self-administered patient-reported outcome (PRO) that assesses symptoms, functioning, and health-related quality of life for participants with non-cystic fibrosis bronchiectasis (NCFBE). It contains 37 items in 8 domains (Respiratory Symptoms, Physical Functioning, Role Functioning, Emotional Functioning, Social Functioning, Vitality, Health Perceptions and Treatment Burden). Each of the 37 items is scored from 1 to 4, and each of the 8 domains scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning. A positive change from Baseline indicates improvement in symptoms. For this outcome measure, change in the respiratory symptoms domain score from Baseline was reported. Baseline refers to most recent assessment on or before study Day 1.
Time frame: Baseline, Week 52
Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs are AEs that occurred on or after the date of first dose of study drugs and within 28 days after the end of treatment.
Time frame: Up to Week 56
Plasma Concentration of Brensocatib in Adults (Main Study)
Time frame: 2 hours (h) post-dose on Day 1; Pre-dose and 2 h post-dose at Weeks 4, 28 and 40; Pre-dose at Weeks 16 and 52
Plasma Concentration of Brensocatib in Adults (PK Substudy)
Time frame: 0.5 h, 2 h, and 4 to 8 h post-dose on Day 1and at Week 28; Pre-dose and 2 h post-dose at Weeks 4 and 48; Pre-dose at Weeks 16 and 52
Plasma Concentration of Brensocatib in Adolescents (Main Study)
Time frame: 0.5 h, 2 h, and 4 to 8 h post-dose on Day 1 and at Week 28; Pre-dose and 2 h post-dose at Weeks 4 and 48; Pre-dose at Weeks 16 and 52
Participants took part in the study at 373 sites in 36 countries from 01 Dec 2020 to 28 Oct 2024.
| Milestone | Brensocatib 10 Milligrams (mg) | Brensocatib 25 mg | Placebo |
|---|---|---|---|
| Started | 583 | 575 | 563 |
| Completed | 458 | 466 | 457 |
| Not completed | 125 | 109 | 106 |
| Withdrew: Adverse event | 10 | 10 | 9 |
| Withdrew: Death | 2 | 4 | 8 |
| Withdrew: Lost to follow-up | 10 | 2 | 4 |
| Withdrew: Physician decision | 2 | 2 | 3 |
| Withdrew: Protocol deviation | 1 | 3 | 2 |
| Withdrew: Withdrawal by subject | 40 | 32 | 37 |
| Withdrew: Reason not specified | 60 | 56 | 43 |
PE was defined as having 3 or more of these symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics: 1. Increased cough 2. Increased sputum volume or change in sputum consistency 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis. A severe pulmonary exacerbation was that required intravenous (IV) antibacterial drug treatment and/or hospitalization. A minimum of 14 days must have occurred between one exacerbation onset and the next. Any exacerbation that occurred less than 14 days from the prior exacerbation was not considered a new exacerbation. Independent adjudication committee with pulmonary physicians adjudicated reported PE events to see if they fulfil the protocol definition. The rate of PE was analyzed using the negative binomial model.
| exacerbation per participant-year | Brensocatib 10 mg | Brensocatib 25 mg | Placebo |
|---|---|---|---|
| Annualized Rate of Pulmonary Exacerbations (PEs) | 1.015 (0.910 to 1.132) | 1.036 (0.927 to 1.157) | 1.286 (1.158 to 1.428) |
PE was defined as having 3 or more of following symptoms for at least 48 hours resulting in physician's decision to prescribe antibiotics:1.Increased cough2.Increased sputum volume or change in sputum consistency3.Increased sputum purulence4.Increased breathlessness \&/or decreased exercise tolerance5.Fatigue \&/or malaise6.Hemoptysis.Severe PE were those requiring IV antibacterial drug treatment \&/or hospitalization. Minimum of 14 days must have occurred between one exacerbation onset and next. Any exacerbation that occurred within 14 days of prior exacerbation was not considered a new exacerbation. Time to first PE was calculated from randomization date to onset date of the first exacerbation. Participants who did not have exacerbation at end of 52-week treatment period were considered as censored at date of Week 52 in Cox proportional hazard model. Independent adjudication committee with pulmonary physicians adjudicated reported PE events to see if they fulfil protocol definition.
| weeks | Brensocatib 10 mg | Brensocatib 25 mg | Placebo |
|---|---|---|---|
| Time to First PE | 49.000 (40.000 to NA) | 50.714 (37.571 to NA) | 36.714 (31.143 to 41.429) |
Responder status was based on percentage of participants who were exacerbation free over 52-weeks of treatment period. Pulmonary exacerbation was defined as having 3 or more of the following symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics: 1. Increased cough 2. Increased sputum volume or change in sputum consistency 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis. A minimum of 14 days must have occurred between one exacerbation onset and the next. Any exacerbation that occurred less than 14 days from the prior exacerbation was not considered a new exacerbation. Independent adjudication committee of pulmonary physicians adjudicated reported PE events to see if they fulfill protocol definition. For discontinuation prior to Week 52 without having experienced a confirmed PE, responder status was imputed by multiple imputation.
| percentage of participants | Brensocatib 10 mg | Brensocatib 25 mg | Placebo |
|---|---|---|---|
| Responder Status for Exacerbation-Free Over the 52-Week Treatment Period | 48.5 | 48.5 | 40.3 |
FEV1 was used to assess lung function and is the maximum amount of air that can be forced out in one second after first second after taking a forced expiration as measured by spirometer. Postbronchodilator FEV1 tests included spirometry tests performed referred to the spirometry performed within 30 minutes after administration of bronchodilator (4 puffs of salbutamol/albuterol, terbutaline or ipratropium). A positive change from baseline indicates an improvement in lung function. Baseline was the most recent non-missing assessment determined as best effort prior to the first dose of the investigational product.
| liter (L) | Brensocatib 10 mg | Brensocatib 25 mg | Placebo |
|---|---|---|---|
| Change From Baseline at Week 52 in Postbronchodilator Forced Expiratory Volume in 1 Second (FEV1) | -0.050 ± 0.0093 | -0.024 ± 0.0099 | -0.062 ± 0.0094 |
Pulmonary exacerbation was defined as having 3 or more of the following symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics: 1. Increased cough 2. Increased sputum volume or change in sputum consistency 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis. A severe PE was defined as those requiring IV antibacterial drug treatment and/or hospitalization. A minimum of 14 days must have occurred between one exacerbation onset and the next. Any exacerbation that occurred less than 14 days from the prior exacerbation was not considered a new exacerbation. Independent adjudication committee with pulmonary physicians adjucated reported PE events to see if they fulfil the protocol definition. The rate of PE was analyzed using the negative binomial model.
| exacerbation per participant-year | Brensocatib 10 mg | Brensocatib 25 mg | Placebo |
|---|---|---|---|
| Annualized Rate of Severe PEs | 0.137 (0.103 to 0.182) | 0.137 (0.105 to 0.179) | 0.185 (0.142 to 0.242) |
The QOL-B is a validated, self-administered patient-reported outcome (PRO) that assesses symptoms, functioning, and health-related quality of life for participants with non-cystic fibrosis bronchiectasis (NCFBE). It contains 37 items in 8 domains (Respiratory Symptoms, Physical Functioning, Role Functioning, Emotional Functioning, Social Functioning, Vitality, Health Perceptions and Treatment Burden). Each of the 37 items is scored from 1 to 4, and each of the 8 domains scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning. A positive change from Baseline indicates improvement in symptoms. For this outcome measure, change in the respiratory symptoms domain score from Baseline was reported. Baseline refers to most recent assessment on or before study Day 1.
| score on scale | Brensocatib 10 mg | Brensocatib 25 mg | Placebo |
|---|---|---|---|
| Change From Baseline at Week 52 in Quality of Life Questionnaire - Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score in Adult Participants | 6.841 ± 0.7706 | 8.575 ± 0.7556 | 4.809 ± 0.7500 |
An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs are AEs that occurred on or after the date of first dose of study drugs and within 28 days after the end of treatment.
| Participants | Brensocatib 10 mg | Brensocatib 25 mg | Placebo |
|---|---|---|---|
| Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Events (TEAEs) | 452 | 440 | 448 |
| nanograms per milliliter (ng/ml) | Brensocatib 10 mg | Brensocatib 25 mg |
|---|---|---|
| Day 1: 2 h post-dose | 40.52 ± 69.1 | 134.9 ± 51.4 |
| Week 4: Pre-dose | 52.60 ± 68.7 | 157.4 ± 70.8 |
| Week 4: 2 h post-dose | 100.5 ± 32.8 | 293.6 ± 35.1 |
| Week 16: Pre-dose | 45.19 ± 55.0 | 131.6 ± 69.0 |
| Pre-dose at Week 28 | 49.30 ± 63.9 | 143.0 ± 64.6 |
| Week 28: 2 h post-dose | 91.79 ± 45.3 | 323.7 ± 40.1 |
| Week 40: Pre-dose | 45.71 ± 54.2 | 136.8 ± 63.4 |
| Week 40: 2 h post-dose | 107.3 ± 45.0 | 302.6 ± 40.7 |
| Week 52: Pre-dose | 45.78 ± 61.7 | 135.4 ± 60.3 |
| ng/ml | Brensocatib 10 mg | Brensocatib 25 mg |
|---|---|---|
| Day 1: 0.5 h post-dose | 34.51 ± 97.9 | 85.13 ± 103.5 |
| Day 1: 2 h post-dose | 44.52 ± 55.0 | 120.0 ± 56.2 |
| Day 1: 4-8 h post-dose | 38.13 ± 52.9 | 108.5 ± 46.9 |
| Week 4: Pre-dose | 57.53 ± 53.4 | 131.3 ± 60.2 |
| Week 4: 2 h post-dose | 100.3 ± 44.1 | 286.7 ± 38.4 |
| Week 16: Pre-dose | 50.24 ± 58.1 | 138.0 ± 64.5 |
| Week 28: Pre-dose | 50.33 ± 54.7 | 124.6 ± 59.8 |
| Week 28: 0.5 h post-dose | 89.75 ± 46.0 | 235.5 ± 53.3 |
| Week 28: 2 h post-dose | 95.33 ± 35.3 | 271.9 ± 46.0 |
| Week 28: 4-8 h post-dose | 86.27 ± 40.7 | 246.4 ± 43.7 |
| Week 40: Pre-dose | 51.80 ± 54.4 | 119.3 ± 51.3 |
| Week 40: 2 h post-dose | 93.74 ± 32.1 | 271.2 ± 45.0 |
| Week 52: Pre-dose | 49.93 ± 72.2 | 131.6 ± 56.5 |
| ng/ml | Brensocatib 10 mg | Brensocatib 25 mg |
|---|---|---|
| Day 1: 0.5 h post-dose | 63.20 ± 51.7 | 109.3 ± 139.1 |
| Day 1: 2 h post-dose | 68.33 ± 32.5 | 202.5 ± 50.7 |
| Day 1: 4-8 h post-dose | 56.07 ± 24.1 | 196.1 ± 52.4 |
| Week 4: Pre-dose | 44.10 ± 64.2 | 126.6 ± 90.4 |
| Week 4: 2 h post-dose | 134.9 ± 52.8 | 432.9 ± 44.3 |
| Week 16: Pre-dose | 40.62 ± 51.6 | 158.1 ± 95.7 |
| Week 28: Pre-dose | 43.74 ± 57.2 | 132.9 ± 96.3 |
| Week 28: 0.5 h post-dose | 123.4 ± 49.1 | 321.6 ± 93.8 |
| Week 28: 2 h post-dose | 118.5 ± 30.5 | 336.9 ± 77.7 |
| Week 28: 4-8 h post-dose | 115.4 ± 27.7 | 309.9 ± 48.0 |
| Week 40: Pre-dose | 37.30 ± 52.5 | 84.39 ± 102.3 |
| Week 40: 2 h post-dose | 110.4 ± 43.9 | 262.8 ± 77.6 |
| Week 52: Pre-dose | 43.02 ± 64.8 | 104.0 ± 57.8 |
Collected over Up to Week 56. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brensocatib 10 mg | 2/582 (0.3%) | 101/582 (17.4%) | 197/582 (33.8%) |
| Brensocatib 25 mg | 4/574 (0.7%) | 97/574 (16.9%) | 213/574 (37.1%) |
| Placebo | 8/563 (1.4%) | 108/563 (19.2%) | 203/563 (36.1%) |
| Event | Brensocatib 10 mg | Brensocatib 25 mg | Placebo |
|---|---|---|---|
| BronchiectasisRespiratory, thoracic and mediastinal disorders | 47/582 | 48/574 | 67/563 |
| PneumoniaInfections and infestations | 11/582 | 13/574 | 16/563 |
| COVID-19Infections and infestations | 4/582 | 9/574 | 6/563 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 3/582 | 1/574 | 6/563 |
| Atrial fibrillationCardiac disorders | 2/582 | 1/574 | 4/563 |
| CataractEye disorders | 1/582 | 0/574 | 3/563 |
| Pancreatitis acuteGastrointestinal disorders | 0/582 | 1/574 | 2/563 |
| Pneumonia aspirationInfections and infestations | 0/582 | 0/574 | 2/563 |
| Pseudomonas infectionInfections and infestations | 2/582 | 2/574 | 2/563 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 2/582 | 1/574 | 2/563 |
| Event | Brensocatib 10 mg | Brensocatib 25 mg | Placebo |
|---|---|---|---|
| COVID-19Infections and infestations | 89/582 | 113/574 | 83/563 |
| HeadacheNervous system disorders | 39/582 | 49/574 | 39/563 |
| NasopharyngitisInfections and infestations | 45/582 | 36/574 | 43/563 |
| CoughRespiratory, thoracic and mediastinal disorders | 41/582 | 35/574 | 36/563 |
| Back painMusculoskeletal and connective tissue disorders | 13/582 | 17/574 | 35/563 |
| Urinary tract infectionInfections and infestations | 27/582 | 30/574 | 33/563 |
The Intent-to-treat (ITT) analysis set included all participants who were randomized.
| Age, Continuous(Years) | Brensocatib 10 mg | Brensocatib 25 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 59.8 ± 15.92 | 60.6 ± 15.78 | 60.0 ± 15.44 | 60.2 ± 15.72 |
| Sex: Female, Male(Participants) | Brensocatib 10 mg | Brensocatib 25 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 385 | 360 | 362 | 1107 |
| Male | 198 | 215 | 201 | 614 |
| Ethnicity (NIH/OMB)(Participants) | Brensocatib 10 mg | Brensocatib 25 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 177 | 164 | 170 | 511 |
| Not Hispanic or Latino | 391 | 397 | 373 | 1161 |
| Unknown or Not Reported | 15 | 14 | 20 | 49 |
| Race/Ethnicity, Customized(Participants) | Brensocatib 10 mg | Brensocatib 25 mg | Placebo | Total |
|---|---|---|---|---|
| Race — American Indian or Alaska Native | 8 | 6 | 9 | 23 |
| Race — Asian | 63 | 64 | 64 | 191 |
| Race — Black or African American | 2 | 5 | 3 | 10 |
| Race — Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 | 2 |
| Race — White | 431 | 430 | 405 | 1266 |
| Race — Other | 15 | 13 | 11 | 39 |
| Race — Unknown or Not Reported | 48 | 46 | 59 | 153 |
| Race — More than one race | 15 | 11 | 11 | 37 |
Showing the first 100 of 373 sites across 36 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2020 to primary completion in Oct 2024, 46 months.
Results were first posted in Dec 2025, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brensocatib